SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Corixa [CRXA] - cancer vaccines
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: SemiBull who wrote (149)5/22/2002 7:51:17 PM
From: SemiBull   of 222
 
Introgen's Anti-Cancer INGN 241 Yields Positive Results

AUSTIN , Texas -(Dow Jones)- Introgen Therapeutics Inc. said a Phase 1 clinical study showed that a single dose of INGN 241 safely killed cancer cells in patients with advanced cancer.

In a press release Wednesday, the company said the study's findings are "very encouraging for clinical development."

INGN-241 contains a gene that makes the cancer-killing MDA-7 protein. Introgen holds an exclusive worldwide license to the patented gene from Corixa Corp. ( CRXA) for all gene therapy applications.

In the trial, a single dose of the drug was injected directly into patients' solid tumors. The tumors were removed 24 to 96 hours later and compared to pretreatment biopsies to determine how far INGN 241 spread in the tumor, how much MDA-7 was produced and how it induced cancer cell death. In all tumors analyzed, investigators found increased expression of MDA-7 associated with apoptosis, or programmed cell death. Apoptosis was observed in as many as 70% of the treated cancer cells.

Introgen's Nasdaq-traded shares closed Tuesday's regular session at $3.88, up 7 cents, or 1.9%. The company reported a loss of $7.9 million, or 37 cents a share, on $228,782 in revenue for the first quarter ended March 31 , its most recently reported results.

Company Web site: introgen.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News